查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1844154

多發性骨髓瘤治療市場按藥物類別、給藥途徑、分銷管道和產品類型分類－2025年至2032年全球預測

Multiple Myeloma Therapeutics Market by Drug Class, Mode Of Administration, Distribution Channel, Product Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，多發性骨髓瘤治療市場將成長至 404.8 億美元，複合年成長率為 7.35%。

關鍵市場統計數據
基準年 2024 229.5億美元
預計年份：2025年 246億美元
預測年份 2032 404.8億美元
複合年成長率 (%) 7.35%

觀點全面介紹了科學突破、不斷發展的治療模式和支付方動態如何共同作用，重新定義多發性骨髓瘤的治療路徑。

多發性骨髓瘤治療處於科學創新、不斷發展的臨床實踐和複雜的商業動態的關鍵交匯點。細胞療法、標靶抗體、小分子藥物和遞送方式的進步正在再形成治療路徑，並重新定義療效、耐受性和長期疾病控制的預期。這些科學進步與治療藥物的生產、報銷和交付方式的結構性變革同步發生，因此，相關人員更需要整合臨床、監管和營運資訊，以製定連貫的戰略規劃。

臨床醫生和醫療系統正在探索更廣泛的治療方法方案，從高度專業的細胞療法到傳統的蛋白酶體抑制劑和免疫調節劑。支付者和政策制定者正根據有關療效和持久性的證據，不斷完善醫保覆蓋框架，並開展基於結果的合約試點計畫。同時，製造商正努力應對更漫長、更複雜的先進療法研發路徑，這需要同時投資於生產能力、低溫運輸物流和專業人才培育。這些動態共同帶來了機會和風險：機會在於為患者帶來變革性益處並獲得差異化的商業性價值；風險則與供應連續性、價格壓力和推廣障礙有關。

本介紹涵蓋了不斷變化的行業格局、關稅對供應鏈和成本的影響、按治療層級和交付管道分類的細分見解、區域細微差別、競爭格局、為行業領導者提供的可操作建議以及調查方法——所有這些都是為了向經營團隊提供平衡的、基於證據的觀點，以指導近期決策和多年規劃。

近期科學突破、監管靈活性和商業性創新如何重塑多發性骨髓瘤的治療路徑、取得模式和競爭需求

多發性骨髓瘤的治療格局正在經歷一場變革性的轉變，這得益於一系列科學突破、監管靈活性和創新商業模式的共同推動。細胞療法和新一代免疫療法正在拓展臨床可行治療方法的邊界，治療模式也正從以細胞毒性藥物為主的序貫治療方案演變為旨在實現更深層次緩解和延長無進展生存期的持續標靶治療。生物標記主導的患者篩選以及診斷準確性的同步提升，使得更合理的治療順序和聯合策略成為可能，提高了治療的個人化程度，同時也增加了臨床決策的複雜性。

監管機構越來越傾向於採用加速核准途徑和真實世界證據來核准並擴大附加檔，從而縮短從概念驗證的時間，同時也增加了對核准後證據生成和藥物安全檢測的需求。在商業性，製造商正在嘗試創新的合約結構，例如基本契約和多方相關人員風險分擔機制，以平衡領先定價和長期價值交付。在營運方面，高成本、產能受限治療方法的興起正在推動製造商、專科醫療機構和物流合作夥伴之間的合作，以管理生產規模的擴大和確保患者公平獲得治療。

成熟的產品組合，例如蛋白酶體抑制劑和免疫調節劑，正透過配方改進和給藥途徑創新進行最佳化，而研發密集型企業則優先發展細胞療法和雙特異性抗體平台。醫療保健系統也正在進行類似的調整，投資建設能夠整合新型治療方法的專科中心和診療路徑，同時兼顧預算和基礎設施的限制。最終，市場環境呈現出快速技術創新、相關人員之間日益增強的相互依存以及與協調生產、臨床應用和報銷相關的執行風險增加的特徵。

了解新關稅措施對下游供應鏈、定價和營運的影響，以及如何維持策略採購和製造的選擇性准入和商業性可行性。

2025年關稅政策為依賴跨境供應鏈和專業生產投入的治療產品帶來了新的營運和商業複雜性。進口關稅的引進或調整不僅影響成品藥，還會影響活性生物製藥材料、一次性生物加工設備和低溫運輸物流服務原料藥。因此，製造商和經銷商正在重新評估其籌資策略、供應商合約和庫存政策，以在限制成本影響的同時，維持供應的連續性。

關稅環境鼓勵企業進行策略轉型，轉向近岸外包和供應商網路多元化，這可以降低關稅波動和地緣政治風險的影響，但合格的新供應商可能需要資本投資和更長的前置作業時間。此外，更高的進口關稅將提升國內生產能力的重要性，並加強與合約研發受託製造機構（CD&M）的夥伴關係，這些機構可以將供應鏈中的某些環節納入企業內部生產。對於生產產量比率、身分控制和低溫運輸管理至關重要的先進療法而言，關稅引發的物流和零件成本變化可能會增加營運複雜性，並延緩患者治療能力的提升。

從定價和報銷的角度來看，關稅帶來的成本壓力要求製造商積極與支付方溝通，建構能夠體現實際價值並在相關人員之間分散風險的商業性安排。製造商應考慮情境規劃，量化關稅對毛利率的潛在成本影響，並確定緩解措施，例如配方調整、包裝設計修改和物流最佳化，以減少對受關稅影響的原料的依賴。摘要：2025年的關稅情勢凸顯了策略性供應鏈彈性規劃、合約重新談判以及對本地能力進行有針對性投資的必要性，以維持市場准入並保障商業性可行性。

針對不同藥物類別、給藥途徑、分銷管道和產品類型的細分市場策略要務將驅動投資和商業化優先事項。

細分市場層面的洞察揭示了不同治療類別、給藥途徑、通路和產品類型所面臨的差異化策略要務。就藥物類別而言，CAR-T療法展現出獨特的開發和商業化模式，其特點是個人化生產、複雜的物流和卓越中心交付模式；而組蛋白去乙醯化酶抑制劑仍然是一類重要的輔助治療藥物，在耐受性和組合方案方面具有發展潛力。免疫調節劑在基礎療法中繼續發揮核心作用，並透過新型製劑和聯合用藥研究進行生命週期管理。特別是，蛋白酶體抑制劑，如Bortezomib、Carfilzomib和Ixazomib，其給藥方案、毒性和實際用藥依從性各不相同，這會影響臨床醫生的選擇。

按劑型分類，可以發現人們越來越傾向於盡可能以患者為中心的給藥方式。靜脈注射對於許多有效的生物製藥和輸液療法仍然至關重要，而口服療法因其便利性和長期維持治療的優勢而備受青睞，但也帶來了依從性管理和藥物相互作用方面的挑戰。從分銷管道動態來看，醫院藥房在住院藥物和輸液藥物方面仍然發揮著重要作用，專科藥房在管理複雜治療方法和協調患者支持服務方面扮演著核心角色，而零售藥房則在口服藥物和維持治療藥物的配發方面發揮作用，這會影響患者依從性計劃和自付費用結構。

最後，品牌學名藥按產品類型分類，其商業策略也各不相同。學名藥和生物相似藥則著重於成本競爭、納入醫保目錄策略以及作為維持治療或專利到期後的快速上市。彌合這些細分市場之間的鴻溝，有助於更清晰地了解在生產規模、患者支持和循證醫學證據生成方面的投資，如何才能對藥物的接受度、依從性和長期治療定位產生最顯著的影響。

比較美洲、中東和非洲以及亞太地區的區域採納率、基礎設施和報銷情況，以確定准入途徑和戰略投資方向。

區域動態將影響新型多發性骨髓瘤療法的推廣速度和運作前提。美洲地區正快速推進創新治療方法的臨床應用，並持續擁有完善的健保報銷體系，支持早期准入計畫。歐洲、中東和非洲地區（EMEA）的推廣速度將因監管協調、區域採購機制和醫療基礎設施的差異而有所不同：高所得的西方市場將加速推廣，而新興市場則優先考慮成本效益高且可擴展的解決方案。

亞太地區的需求促進因素錯綜複雜。一些市場在國家對先進製造能力的投資推動下，正加速新型生技藥品和細胞療法的臨床應用；而其他市場則優先考慮在地化生產和成本控制。不同地區患者族群特徵、併發症模式及醫療服務模式的差異，都會影響理想的產品特性。例如，門診系統優先考慮口服給藥的便利性，而住院模式則強調輸注效率。供應鏈韌性和區域監管溝通策略必須根據當地的基礎設施實際情況進行調整，以確保患者能夠獲得治療並實現永續的商業化。

因此，跨區域計畫必須整合區域性證據產生、適應性定價策略，並在適當情況下投資於區域生產或填充能力。與區域卓越中心、支付方和患者權益組織建立合作關係可以加快接受度和普及率，而透明的價值溝通和靈活的夥伴關係結構對於應對不同的報銷理念和預算限制至關重要。

競爭優勢日益集中在可擴展的生產製造、循證醫學證據產生、支付方參與以及能夠加速患者獲得醫療服務並實現商業性永續性的夥伴關係模式。

多發性骨髓瘤治療公司之間的競爭動態日益取決於核心藥物發現和臨床開發以外的能力。在擴大複雜生物製藥和細胞生產規模方面的組織靈活性、在以結果為導向的醫保報銷談判中積累的經驗，以及生成核准後真實世界證據的能力，如今已成為商業性成功的關鍵決定因素。專注於CAR-T和雙特異性抗體等平台技術的公司正在投資於端到端的價值鏈（從載體生產和冷鏈物流到治療中心培訓），以縮短患者獲得治療的時間並提高治療結果的一致性。

同時，擁有成熟蛋白酶體抑制劑、單株抗體和免疫調節劑等核心產品的現有企業正利用生命週期管理、聯合用藥試驗和給藥途徑最佳化來鞏固和拓展其治療領域。策略聯盟、許可協議和生產合作十分普遍，企業尋求利用外部專業知識來補充自身能力，例如細胞療法生產、用於提高患者依從性的數位化健康解決方案以及用於複雜治療協調的專科藥房夥伴關係。併購活動體現出兩種模式：一是旨在擴大生產規模的補充性收購；二是旨在建構涵蓋藥物發現、開發和商業化的一體化平台的大型策略交易。

從能力角度來看，成功的公司將融合深厚的臨床開發專長、可擴展的生產營運、先進的衛生經濟學證據產生能力以及能夠適應當地支付方要求的靈活商業模式。在病患支援服務、依從性管理和數位化互動工具方面的領先地位，將透過展現能夠簡化病患病人歷程、支持與支付方談判以及藥品目錄定位的實際價值，進一步提升公司的競爭力。

為製造商和相關人員提供切實可行的策略，以確保供應彈性、循證價值、適應性合約和以患者為中心的服務模式，並加速這些模式的推廣應用。

產業領導者應優先採取一系列切實可行的措施，使科學研究潛力與病患和商業性成果相契合。首先，應大力投資提升生產韌性和產能多元化，以降低供應鏈和關稅風險。這包括篩選合格的替代供應商，並與支持生物製藥批量生產和客製化生產的契約製造製造商建立策略聯盟。同時，應將真實世界證據的生成納入早期研發計劃，以支持監管申報、核准後的附加檔擴展以及與支付方的基本契約，並確保數據收集的互通性和地域相關性。

第二，設計以病人為中心的給藥模式，減輕病人用藥負擔，提高用藥依從性。在臨床上適宜的情況下，採用皮下或口服製劑，並整合數位化依從性工具和專科藥局合作，以確保治療的連續性。第三，採用彈性的商業合約模式，使定價與可衡量的療效掛鉤，並探索風險共擔與訂閱式安排，以促進藥物可及性，同時保障長期收入來源。第四，調整區域策略，以因應基礎設施和報銷方面的差異，優先投資於關稅和物流成本顯著影響服務成本的市場中的本地生產和許可業務。

最後，在研發初期，應整合監管、臨床、供應鏈和商業團隊，並加強跨職能能力，以預測推廣障礙並制定切實可行的上市計畫。領導階層也應與卓越中心和患者權益組織建立夥伴關係，以建立信任並加速臨床應用。總而言之，這些建議措施將降低執行風險，支持永續的藥物獲取，並使公司能夠將科學進步轉化為持續的患者和股東價值。

研究途徑方法，結合二手文獻綜述和相關人員訪談，檢驗了臨床、營運和商業性影響。

支持這些見解的研究結合了結構化的二手資料回顧、有針對性的專家訪談和主題綜合分析，從而構建了一個平衡且以實踐為導向的觀點。二手資料分析檢視了同儕審查的臨床文獻、官方監管文件、臨床試驗註冊庫和現有政策聲明，以梳理近期核准、適應症擴展以及臨床實踐的變化。這些資訊來源提供了臨床和監管背景資訊，使我們能夠專注於治療機制、給藥途徑以及證據生成的需求，而無需依賴專有的市場規模或預測數據。

初步研究包括對相關人員，受訪者包括臨床意見領袖、醫院藥局主任、專科藥局經理、物流和生產專家以及支付方顧問。訪談旨在揭示營運限制因素、實施困難以及關稅和供應鏈變化帶來的實際影響。研究對初步研究和次要研究的結果進行三角驗證，以檢驗主題，並確保策略建議既反映宏觀趨勢，也反映實際營運狀況。

我們透過與專家反覆舉辦綜合分析和檢驗研討會，挑戰既有假設並完善結論，從而保持了分析的嚴謹性。調查方法涵蓋了不斷發展的先進醫療製造技術以及可能改變監管和報銷格局的持續政策變化。在適當情況下，我們會專注於存在不確定性的領域，並鼓勵持續收集證據和進行情境規劃，以適應新的發展。

整合治療創新、商業執行和政策動態，這些因素共同決定了多發性骨髓瘤患者獲得治療的速度和商業性成功率。

總之，多發性骨髓瘤的治療格局呈現出快速的技術創新和複雜的營運及商業性需求。儘管科學進步正在拓展可行的治療策略範圍，但要實現大規模的患者獲益，取決於生產製造、物流、支付方參與和臨床應用等各個環節的整合執行。關稅和供應鏈動態變化帶來了新的壓力，需要採取策略性採購、考慮近岸外包以及靈活的合約條款，以維持藥物供應和利潤率。

該報告按藥物類別、給藥途徑、分銷管道和產品類型，重點闡述了在實證實踐、生產規模和患者支援方面進行投資最為有效的領域。區域差異性要求在定價、監管溝通和基礎設施投資等方面採取與當地給藥能力和支付方預期相適應的策略。能夠將科學差異化與卓越營運、可靠的衛生經濟學證據以及風險共用並展現長期價值的適應性商業模式相結合的機構，將在競爭中脫穎而出。

相關人員應持續關注監管動態，投資建設能夠捕捉真實世界結果的數據系統，並在研發早期階段協調跨職能規劃，以最佳化產品上市和市場准入。透過將創新目標與實際執行相結合，治療領域能夠在複雜的商業性環境中加速改善患者療效。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • BCMA標靶CAR T細胞療法在復發性多發性骨髓瘤患者的快速應用
  • 將針對BCMA和GPRC5D的雙特異性抗體平台擴展至早期臨床試驗
  • 在多發性骨髓瘤治療中，微量殘存疾病評估在指導個人化治療決策的應用日益廣泛
  • 過渡到一線四聯誘導療法，合併使用蛋白酶體抑制劑和單株抗體
  • 來自主要生物相似藥的多發性骨髓瘤治療競爭加劇，影響了定價趨勢。
  • 新一代 CELMoD 的出現，在難治性病例中顯示出優於現有 IMiD 的療效。
  • 將真實世界證據與數位健康平台結合，以最佳化患者依從性和治療效果

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 多發性骨髓瘤藥物市場（依藥物類別分類）

  • CAR-T療法
  • 組蛋白去乙醯化酶抑制劑
  • 免疫調節藥物
  • 單株抗體
  • 蛋白酶體抑制劑
    • Bortezomib
    • Carfilzomib
    • Ixazomib

9. 多發性骨髓瘤藥物市場依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

10. 多發性骨髓瘤藥物市場（依分銷管道分類）

  • 醫院藥房
  • 零售藥房
  • 專科藥房

第11章：多發性骨髓瘤藥物市場（依產品類型分類）

  • 品牌
  • 非專利的

12. 多發性骨髓瘤藥物市場（依地區分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：多發性骨髓瘤藥物市場（按組別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國多發性骨髓瘤藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Bristol-Myers Squibb Company
    • Johnson & Johnson
    • Takeda Pharmaceutical Company Limited
    • Amgen Inc.
    • Sanofi SA
    • GlaxoSmithKline plc
    • Karyopharm Therapeutics Inc.
Product Code: MRR-ED54C46E8354

The Multiple Myeloma Therapeutics Market is projected to grow by USD 40.48 billion at a CAGR of 7.35% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 22.95 billion
Estimated Year [2025] USD 24.60 billion
Forecast Year [2032] USD 40.48 billion
CAGR (%) 7.35%

A comprehensive introductory perspective on how scientific breakthroughs, evolving delivery models, and payer dynamics are converging to redefine multiple myeloma care pathways

Multiple myeloma therapeutics sit at a pivotal intersection of scientific innovation, clinical practice evolution, and complex commercial dynamics. Advances in cellular therapies, targeted antibodies, small molecules, and administration modalities are reshaping treatment pathways and redefining expectations for efficacy, tolerability, and long-term disease control. These scientific advances are occurring alongside structural changes in how therapies are manufactured, reimbursed, and delivered to patients, intensifying the need for stakeholders to synthesize clinical, regulatory, and operational intelligence into coherent strategic plans.

Clinicians and health systems are navigating a wider array of therapeutic choices that span highly specialized cell therapies to more conventional proteasome inhibitors and immunomodulatory agents. Payers and policy-makers are responding to evidence on value and durability with evolving coverage frameworks and outcome-based contracting pilots. Meanwhile, manufacturers are contending with longer, more complex development pathways for advanced therapies that require parallel investments in manufacturing capacity, cold-chain logistics, and specialized workforce training. Together, these dynamics create both opportunity and risk: opportunities to deliver transformative patient benefits and capture differentiated commercial value, and risks tied to supply continuity, pricing pressures, and adoption barriers.

This introduction frames the subsequent sections, which examine the landscape shifts, tariff-related impacts on supply chains and costs, segmentation-driven insights across therapeutic classes and delivery channels, regional nuances, competitive behavior, actionable recommendations for industry leaders, and the methodology underpinning the intelligence gathered. The aim is to equip executive teams with a balanced, operationally grounded view that can inform near-term decisions and multi-year planning.

How recent scientific breakthroughs, regulatory flexibility, and commercial innovation are reshaping therapeutic pathways, access models, and competitive imperatives in multiple myeloma

The therapeutic landscape for multiple myeloma is undergoing transformative shifts driven by a confluence of scientific breakthroughs, regulatory adaptability, and commercial model innovation. Cellular therapies and next-generation immunotherapies are extending the boundaries of what is clinically feasible, prompting treatment paradigms to evolve from sequential, cytotoxic-focused regimens toward durable, targeted approaches that aim for deeper remissions and longer progression-free intervals. Parallel enhancements in biomarker-driven patient selection and diagnostic precision are enabling more rational sequencing and combination strategies, increasing the complexity of clinical decision-making while improving personalization of care.

Regulators are increasingly open to accelerated pathways and real-world evidence to inform approvals and label expansions, which shortens the time from proof-of-concept to broader clinical access but elevates the need for robust post-approval evidence generation and pharmacovigilance. Commercially, manufacturers are experimenting with innovative contracting arrangements, including outcomes-based agreements and multi-stakeholder risk-sharing constructs, to balance upfront pricing with long-term value delivery. Operationally, the rise of high-cost, capacity-constrained therapies has catalyzed collaborations between manufacturers, specialized providers, and logistics partners to manage manufacturing scale-up and equitable patient access.

Taken together, these shifts are altering competitive dynamics, with research-intensive players prioritizing cell therapy and bispecific platforms while established product classes such as proteasome inhibitors and immunomodulatory agents are being optimized through formulation changes and administration route innovations. Health systems are likewise adapting by investing in specialized centers of excellence and care pathways that can integrate new therapies while managing budgetary and infrastructure constraints. The net effect is a market environment defined by rapid innovation, increasing interdependence among stakeholders, and heightened execution risk tied to manufacturing, clinical adoption, and reimbursement alignment.

Understanding the downstream supply chain, pricing, and operational implications of new tariff measures and how strategic sourcing and manufacturing choices can preserve access and commercial viability

Tariff policies in 2025 introduced a new layer of operational and commercial complexity for therapeutics that rely on cross-border supply chains and specialized manufacturing inputs. The introduction or recalibration of import tariffs affects not only finished pharmaceutical products but also critical components such as active pharmaceutical ingredients, biologic raw materials, single-use bioprocessing equipment, and cold-chain logistics services. As a result, manufacturers and distributors are reassessing sourcing strategies, supplier contracts, and inventory policies to preserve continuity of supply while containing cost impacts.

The tariff environment has prompted a strategic pivot toward nearshoring and diversification of supplier networks, which can mitigate exposure to tariff volatility and geopolitical risk but may require capital investment and longer lead times to qualify new suppliers. In addition, increased import duties elevate the relative importance of domestic manufacturing capacity and contract development and manufacturing organization partnerships that can internalize some supply chain stages. For advanced therapies, where manufacturing yields, chain-of-identity controls, and cold-chain management are critical, tariff-induced changes to logistics and component costs can translate into higher operational complexity and potentially slower scaling of patient throughput.

From a pricing and reimbursement perspective, tariff-driven cost pressures necessitate proactive engagement with payers to demonstrate real-world value and to structure commercial arrangements that distribute risk across stakeholders. Manufacturers should consider scenario planning that quantifies potential cost impacts of tariffs on gross margins and identifies mitigations such as formulation changes that reduce dependency on tariff-exposed inputs, redesigned packaging, and logistics optimization. In summary, the 2025 tariff landscape underscores the need for strategic supply chain resilience planning, contract renegotiation, and targeted investments in local capacity to preserve access and protect commercial viability.

Segmentation-driven strategic imperatives across drug classes, administration routes, distribution channels, and product types that dictate investment and commercialization priorities

Segment-level insights reveal differentiated strategic imperatives across therapeutic classes, routes of administration, distribution pathways, and product types. Within drug classes, CAR-T therapy represents a distinct development and commercialization paradigm characterized by individualized manufacturing, complex logistics, and center-of-excellence delivery models, while Histone Deacetylase Inhibitors remain an important adjuvant class with opportunities around tolerability and combination regimens. Immunomodulatory drugs continue to play a central role in backbone therapy and are subject to lifecycle management through new formulations and combination studies. Monoclonal antibodies and proteasome inhibitors maintain an essential position in treatment sequencing; notably, proteasome inhibitors such as Bortezomib, Carfilzomib, and Ixazomib each present different administration profiles, toxicity considerations, and real-world adherence implications that influence clinician choice.

Administration mode segmentation highlights the growing preference for patient-centric delivery where feasible: intravenous delivery remains indispensable for many high-efficacy biologics and infusion-based regimens, oral therapies gain traction for convenience and chronic maintenance settings but pose adherence and drug-drug interaction management challenges, and subcutaneous formulations are increasingly developed to reduce clinic time and resource burden. Distribution channel dynamics show that hospital pharmacies continue to be critical for inpatient and infusion-delivered products, specialty pharmacies are central for managing complex therapies and coordinating patient support services, and retail pharmacies play a role in dispensing oral and maintenance medications with implications for patient adherence programs and co-pay assistance structures.

Finally, product type differentiation between branded and generic offerings drives distinct commercial strategies. Branded developers focus on innovation, evidence generation for label expansion, and premium pricing strategies underpinned by differentiated clinical data, whereas generic entrants and biosimilars emphasize cost competitiveness, formulary placement tactics, and rapid adoption in maintenance or post-patent-loss settings. Bridging these segmentation lenses enables a clearer understanding of where investment in manufacturing scale, patient support, and evidence generation will have the most meaningful impact on uptake, adherence, and long-term therapeutic positioning.

Regional adoption, infrastructure, and reimbursement contrasts that determine access pathways and strategic investments across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics shape both the pace of adoption and the operational prerequisites for delivering novel multiple myeloma therapies. The Americas continue to be characterized by high clinical adoption for innovative modalities and an advanced reimbursement ecosystem that supports early access programs; this region also faces pronounced pricing scrutiny and payer-driven value frameworks that require robust real-world evidence and outcomes-based contracting. In Europe, Middle East & Africa, regulatory harmonization, regional purchasing mechanisms, and variable healthcare infrastructure lead to heterogenous adoption timelines, with high-income markets in Western Europe accelerating uptake while emerging markets prioritize cost-effective and scalable solutions.

Asia-Pacific exhibits a complex mosaic of demand drivers: certain markets demonstrate rapid clinical uptake of novel biologics and cell therapies supported by targeted national investments in advanced therapy manufacturing capacity, while others emphasize local production and cost containment. Across regions, differences in patient demographics, comorbidity patterns, and healthcare delivery models influence ideal product profiles, such as a premium on oral convenience in ambulatory care-dominated systems or an emphasis on infusion efficiency in hospital-centric models. Supply chain resilience and local regulatory engagement strategies must be tailored to regional infrastructure realities to ensure patient access and sustainable commercialization.

Cross-region planning should therefore integrate localized evidence generation, adaptive pricing strategies, and investments in regional manufacturing or fill-finish capabilities where appropriate. Establishing partnerships with regional centers of excellence, payers, and patient advocacy organizations can accelerate acceptance and uptake, while transparent value communication and flexible contracting structures are essential to navigate differing reimbursement philosophies and budget constraints.

Competitive differentiation is increasingly anchored in scalable manufacturing, evidence generation, payer engagement, and partnership models that accelerate patient access and commercial sustainability

Competitive dynamics among companies operating in multiple myeloma therapeutics are increasingly defined by capabilities beyond core discovery and clinical development. Organizational agility in scaling complex biologic and cellular manufacturing, experience in navigating outcome-focused reimbursement negotiations, and the capacity to generate post-approval real-world evidence are now central determinants of commercial success. Companies focused on platform technologies such as CAR-T or bispecific antibodies are investing in the end-to-end value chain-ranging from vector production and cryogenic logistics to training of treatment centers-in order to reduce time-to-patient and improve consistency of outcomes.

At the same time, incumbents with established proteasome inhibitors, monoclonal antibodies, or immunomodulatory backbones are leveraging lifecycle management, combination studies, and administration route optimization to defend and extend their therapeutic roles. Strategic alliances, licensing deals, and manufacturing partnerships are common as firms seek to complement internal capabilities with external expertise in cell therapy manufacturing, digital health solutions for adherence, and specialty pharmacy networks for complex therapy coordination. Mergers and acquisitions trends reflect a blend of bolt-on acquisitions to secure manufacturing scale and larger strategic transactions aimed at building integrated platforms across discovery, development, and commercialization.

From a capabilities perspective, companies that succeed will combine deep clinical development expertise, scalable manufacturing operations, sophisticated health economics evidence generation, and nimble commercial models that can adapt to region-specific payer requirements. Leadership in patient support services, adherence management, and digital engagement tools further differentiates companies by smoothing the patient journey and demonstrating real-world value that supports payer negotiations and formulary positioning.

Actionable strategies for manufacturers and stakeholders to secure supply resilience, evidence-driven value, adaptive contracting, and patient-centric delivery models that accelerate uptake

Industry leaders should prioritize a set of pragmatic actions that align scientific potential with deliverable patient and commercial outcomes. First, invest proactively in manufacturing resilience and capacity diversification to mitigate supply chain and tariff risks, including qualification of alternate suppliers and strategic partnerships with contract manufacturers to support both bulk and specialized biologic production. Concurrently, embed real-world evidence generation into early development plans to support regulatory submissions, post-approval label expansions, and value-based contracting with payers, ensuring that data collection is interoperable and geographically relevant.

Second, design patient-centric delivery models that reduce administration burden and enhance adherence. Where clinically appropriate, pursue subcutaneous or oral formulations and integrate digital adherence tools and specialty pharmacy coordination to maintain continuity of care. Third, adopt flexible commercial contracting approaches that align pricing to measurable outcomes, exploring risk-sharing and subscription-style agreements to facilitate access while protecting long-term revenue streams. Fourth, tailor regional strategies to account for differences in infrastructure and reimbursement, prioritizing investments in local manufacturing or licensing in markets where tariffs or logistics materially affect cost-to-serve.

Finally, strengthen cross-functional capabilities by integrating regulatory, clinical, supply chain, and commercial teams early in development to anticipate adoption barriers and create executable launch plans. Leadership should also cultivate partnerships with centers of excellence and patient advocacy organizations to build trust and accelerate clinical uptake. These recommended actions collectively reduce execution risk, support sustainable access, and enable companies to convert scientific advances into durable patient and shareholder value.

A rigorous mixed-methods research approach combining secondary literature synthesis and targeted stakeholder interviews to validate clinical, operational, and commercial implications

The research underpinning these insights combined structured secondary intelligence review, targeted expert interviews, and thematic synthesis to create a balanced, practice-oriented perspective. Secondary analysis included interrogation of peer-reviewed clinical literature, public regulatory filings, clinical trial registries, and available policy statements to map recent approvals, label expansions, and changes in clinical practice. These sources informed the clinical and regulatory context without relying on proprietary market sizing or forecasting data, enabling a focus on therapeutic mechanisms, administration modalities, and evidence generation imperatives.

Primary research involved semi-structured interviews with a cross-section of stakeholders, including clinical opinion leaders, hospital pharmacy directors, specialty pharmacy operators, logistics and manufacturing experts, and payer advisors. Interviews were designed to surface operational constraints, adoption pain points, and the practical implications of tariff and supply chain shifts. Findings from primary and secondary research were triangulated to validate themes and to ensure that strategic recommendations reflect both macro-level trends and on-the-ground operational realities.

Analytical rigor was maintained through iterative synthesis and validation workshops with domain experts to challenge assumptions and refine implications. Limitations of the methodology include the evolving nature of advanced therapy manufacturing technologies and ongoing policy changes that may alter the regulatory and reimbursement landscape. Where appropriate, the research highlights areas of uncertainty and recommends ongoing evidence collection and scenario planning to adapt to emerging developments.

Synthesis of therapeutic innovation, operational execution, and policy dynamics that together determine the pace of patient access and commercial success in multiple myeloma

In conclusion, the therapeutic landscape for multiple myeloma is characterized by rapid innovation coupled with intricate operational and commercial requirements. Scientific advances are expanding the range of viable therapeutic strategies, but realization of patient benefit at scale depends on integrated execution across manufacturing, logistics, payer engagement, and clinical adoption. Tariff and supply chain dynamics have introduced new pressures that necessitate strategic sourcing, nearshoring consideration, and contractual flexibility to preserve access and margins.

Segmentation across drug class, mode of administration, distribution channels, and product type highlights where investments in evidence generation, manufacturing scale, and patient support will be most impactful. Regional heterogeneity requires tailored approaches to pricing, regulatory engagement, and infrastructure investments to match local delivery capabilities and payer expectations. Competitive success will go to organizations that marry scientific differentiation with operational excellence, robust health economics evidence, and adaptive commercial models that share risk and demonstrate long-term value.

Moving forward, stakeholders should continue to monitor regulatory developments, invest in data systems that capture real-world outcomes, and coordinate cross-functional planning early in development to optimize launch and access. By aligning innovation objectives with pragmatic execution, the therapeutic community can accelerate meaningful improvements in patient outcomes while navigating the complex commercial landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of BCMA-targeted CAR T-cell therapies in relapsed myeloma patients
  • 5.2. Expansion of bispecific antibody platforms targeting BCMA and GPRC5D in early clinical trials
  • 5.3. Growing use of minimal residual disease assessment to guide personalized treatment decisions in myeloma
  • 5.4. Shift toward frontline quadruplet induction regimens combining proteasome inhibitors and monoclonal antibodies
  • 5.5. Increasing competition from biosimilar versions of key multiple myeloma biologics impacting pricing dynamics
  • 5.6. Emergence of next-generation CELMoD agents showing improved efficacy over existing IMiDs in refractory cases
  • 5.7. Integration of real-world evidence and digital health platforms to optimize patient adherence and outcomes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Multiple Myeloma Therapeutics Market, by Drug Class

  • 8.1. CAR-T Therapy
  • 8.2. Histone Deacetylase Inhibitor
  • 8.3. Immunomodulatory Drug
  • 8.4. Monoclonal Antibody
  • 8.5. Proteasome Inhibitor
    • 8.5.1. Bortezomib
    • 8.5.2. Carfilzomib
    • 8.5.3. Ixazomib

9. Multiple Myeloma Therapeutics Market, by Mode Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Multiple Myeloma Therapeutics Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Retail Pharmacy
  • 10.3. Specialty Pharmacy

11. Multiple Myeloma Therapeutics Market, by Product Type

  • 11.1. Branded
  • 11.2. Generic

12. Multiple Myeloma Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Multiple Myeloma Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Multiple Myeloma Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Bristol-Myers Squibb Company
    • 15.3.2. Johnson & Johnson
    • 15.3.3. Takeda Pharmaceutical Company Limited
    • 15.3.4. Amgen Inc.
    • 15.3.5. Sanofi S.A.
    • 15.3.6. GlaxoSmithKline plc
    • 15.3.7. Karyopharm Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. MULTIPLE MYELOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. MULTIPLE MYELOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MULTIPLE MYELOMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BORTEZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CARFILZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IXAZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IXAZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IXAZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 176. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 178. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 190. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 191. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 192. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 214. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 215. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 216. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 217. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 218. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 219. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 226. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 227. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 228. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 229. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 250. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 251. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 252. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 253. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 254. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 255. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 262. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 263. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 264. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 265. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 274. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 275. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 276. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 277. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 278. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 279. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 287. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 289. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 296. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 297. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 298. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 299. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)

TABL